* If you want to update the article please login/register
By comparing these patients to those aged 65 years, Aim To determine the findings of primary concurrent chemoradiation therapy with triweekly cisplatin in patients with head and neck squamous cell carcinoma aged u226565 years. Methods This prospective, single-center research enrolled patients with HNSCC for whom CCRT was indicated as the primary treatment. Patients were between 192. 8 mg/m 2 and 212. 3 mg/m 2 in patients with u226565 and 65, respectively. According to the age u226565 and 65 groups, the incidence rates of any grade 3-4 toxicities were 34. 3 percent and 51. 1 percent. Age u226565 years was not associated with increased risk of treatment failure in a Cox regression study, but it was associated with a higher overall death rate. Conclusions CCRT with a triweekly cisplatin regimen may have the same caliber HNSCC in elderly patients as the gold standard of care for HNSCC.
Source link: https://europepmc.org/article/MED/36178306
The new gold standard-of-care in curative-intent therapy of loco-regionally advanced head and neck squamous cell carcinoma is Cisplatin-based concurrent chemoradiotherapy. The majority of evidence in favour of cisplatin-based chemoradiotherapy is based on high-dose cisplatin, which is available as 100 mg/m 2 every three weeks for up to three cycles. With nearly 40% of patients failing to finish the third cycle in a row, the third cycle is reportedly suboptimal, despite a cumulative cisplatin dose of 200 mg/m 2 that is generally considered adequate for therapeutic anti-tumor therapy. Such low-dose weekly regimens have undergone less rigorous prospective study compared to RT alone, but they are still widely used in co-operative group trials and routine clinical practice. Increasing evidence that chemoradiotherapy with once-weekly cisplatin is non-inferior to three-weekly cisplatin for disease-related outcomes in loco-regionally advanced head and neck cancer curative-intent care.
Source link: https://europepmc.org/article/MED/36162191
Our aim: and end In patients with locally advanced esophageal cell carcinoma who underwent chemoradiotherapy, a neoadjuvant chemoradiotherapy was studied and compared the efficacy and safety of chemotherapy with paclitaxel plus carboplatin or carboplatin cisplatin or carboplatin chemoradiotherapy. Materials and methods This single-center retrospective review examined patients with LA-ESCC who were receiving NCRT enhanced curative-intent esophagectomy with TP or TC regimens. The TC and TP groups' respective samples contained 151 and 50 patients. The TP group had notably higher hematologic and non-hematologic AEs than the TC group, and the notable difference was the prevalence of febrile neutropenia in grade 3 or higher. According to TP and TC groups, the estimated 3-year OS and PFS rates were 61% versus 66. 4 percent and 55% versus 55%. Given the superior safety profile and comparable efficacy in patients with LA-ESCC, we recommend TC, not TP, as the best chemotherapy regimen for NCRT.
Source link: https://europepmc.org/article/PPR/PPR549882
We retrospectively reviewed cisplatin-ineligible patients with mUC who underwent first-line ICI monotherapy or ICI plus chemotherapy at two medical centers in Taiwan from 2016 to 2021. In total, 130 patients were registered and divided into two groups, an ICI monotherapy group [immunotherapy n=101] and an ICI plus noncisplatin chemotherapy group [immunotherapy and chemotherapy, n=29]. The median OS in the IO group was much longer than in the IC group compared to the IC group. With mUC, first-line ICI monotherapy demonstrated strong antitumor activity in cisplatin-ineligible patients.
Source link: https://europepmc.org/article/MED/36121316
Although some pre-programmed cell death -1 inhibitors are approved for the first-line treatment of advanced urothelial carcinoma, clinical urothelial carcinoma in cisplatin-ineligible patients with upper tract urothelial carcinoma, as well as gemcitabine plus carboplatin, remains unclear in cisplatin-ineligible patients with upper tract urothelial carcinoma. Patients with UTUC were retrospectively extracted from nine hospitals' electronic medical records between 2018 and 2021. Patients were deemed ineligible for cisplatin who were either PD-1 inhibitors or gemcitabine plus carboplatin. In the PD-1 inhibitor group, there were 18 months in the PD-1 inhibitor group, relative to 14 months in the carboplatin-gemcitabine group. In the PD-1 inhibitor group than in the carboplatin-gemcitabine group, the duration of reaction was significantly longer than in the carboplatin-gemcitabine group. In the PD-1 inhibitor group than in the carboplatin-gemcitabine group, treatment-related adverse events were less common in the treatment-related adverse events than in the carboplatin-gemcitabine group. In the first-line treatment of UTUC in patients eligible for cisplatin-based chemotherapy, PD-1 inhibitors demonstrated promising safety with less toxicity and longer DOR.
Source link: https://europepmc.org/article/MED/36148322
Background To date, there have been no clinical trials on induction therapy before surgery that have solely focused on lung squamous cell carcinoma. S-1 + cisplatin has been used in tandem thoracic radiotherapy and surgery in patients with stage IIIA LSCC, according to the results of the Personalized Induction Therapy-2 trial, a multicenter phase II study, to investigate the effectiveness and safety of S-1 + cisplatin. Patients with pathologically evident stage IIIA LSCC were treated to induction therapy involving three cycles of S-1 + cisplatin with simultaneous TRT followed by surgery. After discharge, one case of 90-day postoperative mortality involved a patient who underwent right pneumonectomy and pneumonia after discharge occurred. Induction therapy using S-1 + cisplatin with simultaneous TRT and surgery is a cost-effective and promising therapy strategy for stage IIIA LSCC.
Source link: https://europepmc.org/article/MED/36097299
In our previous phase 3 study, patients with locally advanced oral squamous cell carcinoma failed to profit from docetaxel, cisplatin, and 5-fluorouracil neoadjuvant chemotherapy prior to surgery and postoperative radiotherapy. In this review, a retrospective review of 65 patients with Ki67 expression below 25% or above 50% was retrospectively reviewed. Among the 65 patients included in the study, those with elevated Ki67 expression before treatment had better overall survival and distant metastasis free survival than those with low expression. According to a positive effect on the OS, a high Ki67 peak before TPF neoadjuvant chemotherapy had a positive effect on the OS. Conclusions: High Ki67 expression before therapy may indicate the survival benefits of TPF neoadjuvant chemotherapy in patients with locally advanced OSCC, which may act as a biomarker for personalized care.
Source link: https://europepmc.org/article/PPR/PPR541762
Oral squamous cell carcinoma is the sixth most common malignancy worldwide, according to the author's study. Objection and Objectives : Oral squamous cell carcinoma is the sixth most common malignancy in the world. Multiple types of tumors have been shown to be involved in angiogenesis by the transient receptor potential vanilloid 4 channel. The RT 2 Profiler PCR array was used to analyze TRPV4, vascular growth factors that correlate specifically with angiogenesis, such as angiopoietin and tyrosine kinase receptors, while angiopoietin are visible, as shown by angiogenesis, such as angiopoietin and tyrosine kinase receptors, in particular. Following the introduction of a combination of GSK1016790A and cisplatin, a RT 2 profiler PCR array demonstrated significant rises of Ang-1 and Tie-2 in OSCC. In addition, the combination treatment significantly reduced the microvessel density and significantly raised the number of microvessels coated with pericytes in OSCC. In addition, tumor size in rats that were cisplatin alone was drastically reduced. The findings indicate that treating a TRPV4 agonist with cisplatin for OSCC treatment may lead to vessel normalization by modulation of the Ang-1/Tie-2 pathway.
Source link: https://europepmc.org/article/MED/36143906
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions